Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023)
Inter-individual variations in drug responses are major concerns in cancer treatment in human and veterinary oncology. Consequently, preclinical models have been proposed to predict drug responses and determine optimal individualized therapy. We aimed to evaluate the clinical utility of in vitro dru...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/15/8/1146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850183748408049664 |
|---|---|
| author | Young-Rok Kim Kieun Bae Ja-Young Lee Soon-Wuk Jeong Hun-Young Yoon Hyun-Jung Han Jae-Eun Hyun Aryung Nam Ji-Hwan Park Kyong-Ah Yoon Jung-Hyun Kim |
| author_facet | Young-Rok Kim Kieun Bae Ja-Young Lee Soon-Wuk Jeong Hun-Young Yoon Hyun-Jung Han Jae-Eun Hyun Aryung Nam Ji-Hwan Park Kyong-Ah Yoon Jung-Hyun Kim |
| author_sort | Young-Rok Kim |
| collection | DOAJ |
| description | Inter-individual variations in drug responses are major concerns in cancer treatment in human and veterinary oncology. Consequently, preclinical models have been proposed to predict drug responses and determine optimal individualized therapy. We aimed to evaluate the clinical utility of in vitro drug sensitivity testing using a patient-derived cell culture model to select appropriate adjuvant therapies for dogs with solid tumors. We screened medical records of 126 dogs with suspected tumors, including 33 dogs with solid tumors (guided group, 16; empirical group, 17). Anticancer drugs used for adjuvant therapy were determined based on in vitro drug sensitivity testing (guided group) or histopathological examination (empirical group) results. Time to tumor progression (TTP) was compared between groups. The guided group had significantly longer TTP than the empirical group (949 vs. 109 days). Median TTPs were significantly longer in the guided group than in the empirical group for dogs with incomplete surgical margin (949 vs. 109 days), dogs with mitotic count < 20 per 10 high power fields (949 vs. 105 days), dogs with no evidence of metastatic disease at initial diagnosis (455 vs. 196 days), and dogs receiving tyrosine kinase inhibitors (949 vs. 109 days). Our study suggests that in vitro drug sensitivity testing may be a useful tool for optimizing adjuvant therapy in dogs with solid tumors. |
| format | Article |
| id | doaj-art-e64552eabb91463b87eb0d5cc7c18272 |
| institution | OA Journals |
| issn | 2076-2615 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj-art-e64552eabb91463b87eb0d5cc7c182722025-08-20T02:17:14ZengMDPI AGAnimals2076-26152025-04-01158114610.3390/ani15081146Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023)Young-Rok Kim0Kieun Bae1Ja-Young Lee2Soon-Wuk Jeong3Hun-Young Yoon4Hyun-Jung Han5Jae-Eun Hyun6Aryung Nam7Ji-Hwan Park8Kyong-Ah Yoon9Jung-Hyun Kim10KU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaBundang Leaders Animal Medical Center, Seongnam 13636, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaKU Animal Cancer Center, Konkuk University Veterinary Medical Teaching Hospital, Seoul 05029, Republic of KoreaInter-individual variations in drug responses are major concerns in cancer treatment in human and veterinary oncology. Consequently, preclinical models have been proposed to predict drug responses and determine optimal individualized therapy. We aimed to evaluate the clinical utility of in vitro drug sensitivity testing using a patient-derived cell culture model to select appropriate adjuvant therapies for dogs with solid tumors. We screened medical records of 126 dogs with suspected tumors, including 33 dogs with solid tumors (guided group, 16; empirical group, 17). Anticancer drugs used for adjuvant therapy were determined based on in vitro drug sensitivity testing (guided group) or histopathological examination (empirical group) results. Time to tumor progression (TTP) was compared between groups. The guided group had significantly longer TTP than the empirical group (949 vs. 109 days). Median TTPs were significantly longer in the guided group than in the empirical group for dogs with incomplete surgical margin (949 vs. 109 days), dogs with mitotic count < 20 per 10 high power fields (949 vs. 105 days), dogs with no evidence of metastatic disease at initial diagnosis (455 vs. 196 days), and dogs receiving tyrosine kinase inhibitors (949 vs. 109 days). Our study suggests that in vitro drug sensitivity testing may be a useful tool for optimizing adjuvant therapy in dogs with solid tumors.https://www.mdpi.com/2076-2615/15/8/1146adjuvant therapydogin vitro drug sensitivity testingpersonalized therapysolid tumor |
| spellingShingle | Young-Rok Kim Kieun Bae Ja-Young Lee Soon-Wuk Jeong Hun-Young Yoon Hyun-Jung Han Jae-Eun Hyun Aryung Nam Ji-Hwan Park Kyong-Ah Yoon Jung-Hyun Kim Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) Animals adjuvant therapy dog in vitro drug sensitivity testing personalized therapy solid tumor |
| title | Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) |
| title_full | Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) |
| title_fullStr | Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) |
| title_full_unstemmed | Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) |
| title_short | Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023) |
| title_sort | clinical utility of patient derived cell based in vitro drug sensitivity testing for optimizing adjuvant therapy in dogs with solid tumors a retrospective study 2019 2023 |
| topic | adjuvant therapy dog in vitro drug sensitivity testing personalized therapy solid tumor |
| url | https://www.mdpi.com/2076-2615/15/8/1146 |
| work_keys_str_mv | AT youngrokkim clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT kieunbae clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT jayounglee clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT soonwukjeong clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT hunyoungyoon clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT hyunjunghan clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT jaeeunhyun clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT aryungnam clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT jihwanpark clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT kyongahyoon clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 AT junghyunkim clinicalutilityofpatientderivedcellbasedinvitrodrugsensitivitytestingforoptimizingadjuvanttherapyindogswithsolidtumorsaretrospectivestudy20192023 |